Boston Biomedical, a company focused on the research and development of novel cancer therapeutics targeting cancer stem cells (CSC), provided a summary of the clinical data presented at the 2014 American Society of Clinical Oncology (ASCO) 50th annual meeting, held in Chicago, Ill. Clinical data were presented for BBI608 and BBI503, novel agents targeting cancer stem cells that have been developed by the company. BBI608 is a first-in-class cancer cell stemness inhibitor that blocks CSC self-renewal and induces cell death in CSC through blocking beta-catenin and Stat3 pathways. BBI503 is a first-in-class cancer stemness kinase inhibitor also targeting CSC self-renewal and survival. A Phase 1b study of BBI608 and a Phase 1 study of BBI503 were part of the Poster Highlights Session. The BBI503 study has also been selected to be one of the three presentations in the Developmental Therapeutics session at Best of ASCO 2014 in Japan.
“Data showed encouraging signs of anticancer activity of BBI608 and BBI503 in multiple tumor types,” said Dr. Chiang Li, president, CEO and chief medical officer of Boston Biomedical and head of Global Oncology for Dainippon Sumitomo Pharma Group. “Based on the results of these and additional studies, we have initiated a global pivotal study of BBI608 plus weekly paclitaxel in patients with gastric/GEJ cancer. In addition, a Phase 1 study of BBI503 showed potent inhibition of cancer stemness biomarker in patient tumor tissues as well as a good safety profile without typical kinase inhibitor toxicities. Prolonged disease stabilization was observed in 45% of all evaluable patients. Phase 2 studies of BBI503 are ongoing or are being planned.”
Date: June 16, 2014
Source: Boston Biomedical
